What does NeurAxis do?
NeurAxis, Inc. is a growth-stage medical technology company listed on the NYSE American under NRXS. Its commercial focus is neuromodulation for disorders of gut-brain interaction, especially chronic functional abdominal pain in children and adolescents. The company’s core product, IB-Stim, is a prescription, non-implantable device that delivers percutaneous electrical nerve field stimulation, or PENFS, through small electrodes placed around the ear. The therapy is intended to modulate central pain-processing pathways rather than treat the gastrointestinal tract directly. NeurAxis describes the platform and its clinical purpose on its official corporate website.
Which patients and providers are the target market?
IB-Stim is used in outpatient care by trained clinicians, principally pediatric gastroenterologists and children’s hospitals. The FDA de novo decision summary supports the original regulatory pathway. The FDA-cleared use covers patients age eight and older with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. A typical course uses one device per week for four consecutive weeks, with each device worn for roughly five days. The 2025 Form 10-K states a list price of $1,195 per device, implying a gross four-device course value of $4,780 before reimbursement terms, discounts, and patient-assistance adjustments. NeurAxis sells primarily to hospitals and private physician practices rather than directly to patients.
FDA-cleared PENFS therapy and the company’s sole reportable segment. Revenue depends on provider adoption, prior authorization, payer coverage, and device utilization.
A related product launched in 2025. It contributed to annual sales growth but remains secondary to IB-Stim and faces coding uncertainty disclosed in the annual report.
Clinical programs include post-concussion syndrome, cyclic vomiting syndrome, post-operative pain, and fibromyalgia-related pain.
How does NeurAxis make money?
NeurAxis is fundamentally a device-sales business. Revenue is recognized when IB-Stim or RED devices are delivered to healthcare customers, generally under purchase orders with standard net-30 terms. It does not yet have a recurring subscription model, a large installed-base service stream, or long-duration purchase commitments. That makes sales sensitive to the number of trained providers, approved patients, payer policies, prior-authorization success, and the mix between full-reimbursement customers and discounted financial-assistance programs.
Published outcomes support physician confidence and payer discussions.
CPT 64567 and insurer policies make claims processing clearer.
Hospitals and practices complete training and identify candidates.
Each standard treatment course creates multiple unit sales.
High product margin supports selling, clinical, and public-company costs.
Why reimbursement matters more than manufacturing volume
The product’s gross margin is high, but its commercial bottleneck is access rather than factory capacity. The company reported that 24 commercial health insurers had formal PENFS medical policies covering nearly 100 million lives as of the 2025 annual report. The Category I CPT code 64567 became effective January 1, 2026, replacing the temporary Category III framework. Management links the first-quarter 2026 sales acceleration directly to that coding milestone and broader insurance coverage. The economic logic is therefore unusual: small changes in reimbursement breadth can produce large changes in order volume because the manufacturing cost per device is modest relative to selling price.
Which revenue concentration matters?
Customer concentration is material. The two largest customers represented 28% of FY2025 net sales, down from 35% in FY2024. One customer contributed 14% and another 14% in FY2025. Because sales are purchase-order based, losing a large account or experiencing delayed orders can noticeably affect a small quarterly revenue base. The commercial objective is not merely to add accounts, but to broaden the mix of hospitals, private practices, and covered payers so that no single purchasing relationship determines a quarter.
What does the latest quarter show?
The quarter ended March 31, 2026 is the clearest early test of the Category I CPT transition. According to the Q1 2026 Form 10-Q, net sales rose 79.5% year over year to $1.608 million. Gross profit increased to $1.390 million, and gross margin improved by 2.0 percentage points to 86.4%. The company still reported a sizable operating loss, but the loss narrowed as higher gross profit and lower general and administrative expense outweighed a significant expansion in selling expense.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Net sales | $1.608M | $0.896M | Growth reflects fuller reimbursement and broader coverage. |
| Gross profit | $1.390M | $0.756M | High incremental gross profit supports operating leverage. |
| Operating loss | $(1.741)M | $(2.295)M | Improved 24.2%, but expenses remain far above revenue. |
| Operating cash use | $(1.230)M | $(1.604)M | Cash burn improved 23.3% year over year. |
What changed inside the cost structure?
Selling expense rose 64.8% to $824,336 in Q1 2026 as commissions, sales representatives, and marketing personnel expanded to support the reimbursement opportunity. Research and development expense declined 15.5% to $99,567, while general and administrative expense fell 9.3% to $2.206 million, partly because a prior-year lawsuit charge did not recur. This mix shows the central operating tension: NeurAxis must spend aggressively to convert coding progress into provider adoption, yet its public-company overhead remains large relative to revenue.
How did reimbursement reshape NeurAxis’s strategy?
NeurAxis’s history is best understood as a sequence from scientific validation to regulatory clearance and then to reimbursement infrastructure. The device existed before the economic pathway was mature. That distinction matters because FDA clearance permits marketing, while coding and payer policy determine whether hospitals can routinely deliver the therapy without placing excessive financial burden on families.
-
2012The company was founded around PENFS technology, creating the platform that later became IB-Stim.
-
2017A randomized, double-blind, sham-controlled pediatric study strengthened the evidence base for neuromodulation in functional abdominal pain.
-
2019FDA de novo clearance established IB-Stim as a Class II device and created a defined PENFS product classification.
-
2022Temporary Category III CPT code 0720T became effective, allowing utilization tracking but not yet the mature reimbursement framework of a Category I code.
-
2023NeurAxis completed its public listing and launched an internal prior-authorization and patient-support function to reduce access friction.
-
2024–2025The AMA accepted and finalized Category I CPT code 64567; insurer policies expanded and the RED device entered the commercial mix.
-
2026CPT 64567 became effective on January 1, turning reimbursement execution into the dominant near-term growth driver.
Why the Category I code is a strategic asset, not a moat by itself
The Category I code gives physicians a standardized way to report PENFS procedures and provides relative value units for professional work. It can improve claim transparency and reduce uncertainty, but it does not guarantee coverage, favorable fee schedules, or payment by every payer. NeurAxis must still win medical-policy decisions, train providers, support prior authorizations, and demonstrate outcomes. The code lowers friction; it does not eliminate commercial execution risk.
What gives NeurAxis a competitive advantage?
NeurAxis’s strongest advantage is the combination of regulatory clearance, clinical evidence, procedure-specific coding, and an early hospital footprint. The company’s investor-relations materials emphasize that IB-Stim is a drug-free neuromodulation option for chronic conditions with substantial unmet need. In a pediatric setting, avoiding systemic drug exposure and serious adverse events can be strategically meaningful, especially for patients who have already cycled through medications.
How defensible is the clinical and regulatory position?
The 2025 annual report cites a multicenter registry of 292 pediatric patients, with 92% having failed medication therapy and 61% having failed four or more medications. It also reports randomized evidence showing meaningful symptom improvement versus sham treatment. Those data can support physician adoption and insurer reviews. FDA classification and indication-specific clearance create entry barriers because a rival must establish safety, effectiveness, manufacturing quality, and reimbursement credibility rather than merely reproduce hardware.
Who are the practical competitors?
The competitive set includes pharmaceutical therapy, dietary intervention, cognitive behavioral therapy, guided imagery, other neuromodulation approaches, and watchful management by specialists. Buyer power is meaningful because hospitals and insurers can delay adoption or demand stronger evidence. Substitution risk is also high: a clinician may choose medication or behavioral therapy even when the mechanism differs. NeurAxis differentiates through a non-drug, outpatient treatment course and an evidence base tailored to pediatric disorders of gut-brain interaction, but it must prove that the pathway is simpler and economically acceptable for providers.
| Alternative | Patient appeal | Constraint | NeurAxis positioning |
|---|---|---|---|
| Medication | Familiar and broadly available | Side effects and incomplete response | Drug-free option for refractory patients |
| Behavioral therapy | Evidence-based, non-drug care | Access to trained therapists | Outpatient device with standardized course |
| Other neuromodulation | Potential mechanism overlap | Different indications and evidence | Pediatric GI-specific clearance and coding |
How financially strong is NeurAxis?
NeurAxis has attractive product economics but not yet a self-funding corporate model. FY2025 sales were $3.569 million, up 32.9%, and gross profit was $3.006 million. Yet the company recorded a $7.830 million operating loss and a $7.801 million net loss because selling, research, and general administrative costs greatly exceeded gross profit. The 2025 Form 10-K is explicit that significant expenses and operating losses are expected while coverage and additional indications are pursued.
| FY2025 metric | Value | FY2024 comparison | Research implication |
|---|---|---|---|
| Net sales | $3.569M | $2.686M | 32.9% growth from volume, coverage, and RED launch. |
| Gross margin | 84.2% | 86.5% | Discounted assistance mix and expired RED inventory pressured margin. |
| Operating loss | $(7.830)M | $(7.157)M | Revenue remains too small to absorb overhead. |
| Net loss | $(7.801)M | $(8.242)M | Other expense improved, but the core operation remained deeply loss-making. |
What does the balance sheet say about runway?
Cash and cash equivalents were $7.079 million at March 31, 2026, up from $4.965 million at year-end 2025. Working capital was $5.329 million. However, that improvement came mainly from financing: during Q1 2026 the company received $2.990 million of gross proceeds from at-the-market common-stock sales and $507,035 from warrant exercises. Operating activities consumed $1.230 million in the quarter. The company therefore had roughly 5.8 quarters of cash at the Q1 2026 burn rate before considering future changes in revenue, spending, working capital, or financing. That is a simple analytical ratio, not management guidance.
Why dilution is part of the financial model
The company’s SEC EDGAR filing page shows the continuing sequence of financing and ownership filings. Common shares outstanding increased from 10.653 million at December 31, 2025 to 11.450 million at March 31, 2026, and then to 12.384 million by May 8, 2026. The company also had 1.166 million warrants outstanding at March 31, 2026, 1.265 million unvested restricted stock units, and 1.319 million outstanding stock options. These instruments can support employee retention and financing, but they also make per-share valuation sensitive to the fully diluted share count.
Which KPIs best explain NeurAxis’s performance?
Traditional revenue and margin metrics are necessary but incomplete. The leading indicators are reimbursement coverage, hospital penetration, full-reimbursement patient mix, and cash burn. These measures connect clinical acceptance to financial output. A quarter can show excellent gross margin yet still disappoint if provider adoption stalls or financing needs accelerate.
| KPI | Latest disclosed signal | How to interpret it |
|---|---|---|
| Covered lives | Approaching 100M, FY2025 disclosure | Measures addressable reimbursement reach, not actual utilization. |
| Formal insurer policies | 24 commercial insurers, FY2025 disclosure | Policy wins can unlock provider confidence and patient access. |
| Hospital footprint | About 80 of 260 targeted hospitals | Approximately 31% penetration leaves room for expansion. |
| Gross margin | 86.4% in Q1 2026 | Reflects reimbursement mix, pricing, and manufacturing cost. |
| Operating cash use | $1.230M in Q1 2026 | Determines financing runway and dilution risk. |
What is the most important conversion equation?
The practical formula is: covered payer lives × eligible diagnosed patients × provider adoption × authorization success × four devices per standard course × realized selling price. Each term can constrain the result. “Covered lives” alone can look impressive but will not create revenue unless physicians identify candidates, patients accept treatment, and claims are approved. Researchers should therefore compare growth in sales with changes in selling expense and accounts receivable to judge whether commercialization is becoming more efficient.
Who owns NeurAxis stock, and why does governance matter?
NeurAxis has one-vote common stock plus Series B preferred stock that votes on an as-converted basis, subject to holder-specific voting caps. The 2026 proxy statement reported 11.505 million common shares outstanding at the April 14, 2026 record date and 2.378 million additional votes attributable to Series B preferred stock, for 13.883 million total votes before application of ownership caps.
| Holder or group | Beneficial ownership | Voting power | Proxy date implication |
|---|---|---|---|
| Brian P. Hannasch | 10.6% | 8.8% | Largest disclosed individual holder. |
| Rosalind Master Fund LP | 9.3% | 7.9% | Preferred conversion and cap mechanics matter. |
| Bigger Capital Fund LP | 7.2% | 6.0% | Meaningful outside investor influence. |
| Executives and directors, nine persons | 21.1% | 17.6% | Management and board have substantial economic alignment. |
How do incentives affect per-share analysis?
Chief Executive Officer Brian Carrico beneficially owned 2.9% of common stock at the proxy date, including 320,000 options. The executive and director group’s 21.1% beneficial ownership includes exercisable options and other rights, so its economic alignment is meaningful but not equivalent to outright common shares alone. In January 2026, the company granted 437,431 restricted stock units that vest annually over three years. Equity awards may help retain a small specialized team, while also increasing dilution if growth does not outrun share issuance.
What opportunities could expand the story?
The largest near-term opportunity is deeper utilization inside the existing pediatric GI indication. Approximately 80 children’s hospitals were using IB-Stim against a target universe of 260, leaving a substantial whitespace opportunity before considering private practices or adult specialists. Broader fee schedules, cleaner claim processing, and payer-policy wins could increase both treatment volume and the proportion of sales made at full reimbursement.
How much option value sits in additional indications?
Pipeline expansion could be transformative because the same core PENFS platform may address multiple pain-related conditions. The company has disclosed a randomized post-concussion study and a cyclic vomiting study designed for at least 120 patients, alongside work in post-operative pain and fibromyalgia. Yet these programs should be treated as option value rather than base revenue. They require successful trials, regulatory clearance, coding, payer acceptance, provider education, and funding. The existing IBS and functional dyspepsia market must carry the business until those steps are complete.
What risks could weaken NeurAxis’s outlook?
The dominant risk is that commercial adoption may not scale fast enough to fund the cost base. NeurAxis generated only $3.569 million of FY2025 sales against $11.399 million of selling, R&D, and G&A expense. Even after strong Q1 2026 growth, the company remained loss-making and reliant on equity financing. This makes execution risk, reimbursement risk, and dilution risk inseparable.
| Risk | Financial channel | Concrete indicator |
|---|---|---|
| Coverage or payment delays | Lower unit volume and more discounted sales | Payer-policy count, authorization success, gross margin |
| Slow provider adoption | Selling expense rises before revenue | Hospital count and sales per active account |
| Clinical or regulatory setbacks | Delayed indication expansion and impaired pipeline value | Trial enrollment, endpoints, FDA submissions |
| Capital-market dependence | Share dilution or constrained growth spending | Quarterly cash burn and fully diluted shares |
| Internal-control weakness | Higher compliance cost and reporting risk | Remediation disclosures and auditor findings |
What filing-specific risks deserve extra attention?
The 2025 Form 10-K reported that disclosure controls and procedures were not effective at year-end. That does not by itself mean the financial statements were misstated, but remediation can consume cash and management attention. Product economics also face inventory expiration, fixed-price third-party manufacturing contracts, and reimbursement coding risk. The company stated that failure to maintain adequate CPT coding or reimbursement could reduce physicians’ willingness to prescribe the therapy.
Why does NeurAxis matter for valuation?
A conventional mature-company DCF is difficult because NeurAxis has negative free cash flow, rapid but volatile growth, evolving reimbursement, and a changing share count. The valuation question is therefore a probability-weighted commercialization problem. Analysts must estimate how many hospitals and practices adopt IB-Stim, how quickly covered patients convert into treatments, what realized price and gross margin persist, and how much selling and administrative expense is required to support each revenue level.
Which assumptions dominate a DCF?
The most sensitive assumptions are revenue growth through 2030, sustainable gross margin, the steady-state selling and G&A ratio, clinical-development spending, and dilution. Terminal value should carry a high risk adjustment because one product platform, reimbursement dependence, regulatory requirements, and small-company financing create concentrated uncertainty. Comparable-company analysis is also challenging: larger medical-device peers have broader portfolios, stronger balance sheets, and established distribution, while early commercial peers may differ materially in reimbursement and clinical maturity.
| Valuation driver | Bullish evidence | Required skepticism |
|---|---|---|
| Revenue growth | Q1 2026 sales grew 79.5% | One quarter after a coding change is not a mature run rate. |
| Gross margin | 86.4% in Q1 2026 | Discounting, mix, and manufacturing costs can fluctuate. |
| Operating leverage | Operating loss improved 24.2% | G&A remains larger than revenue. |
| Per-share value | ATM financing extends runway | Common stock, warrants, RSUs, and options expand dilution. |
What is the key takeaway from NeurAxis analysis?
NeurAxis is an unusually focused medical-device company whose strategic value rests on turning a clinically supported neuromodulation platform into a reimbursed standard of care. The investment-research story is not primarily about manufacturing scale. It is about whether evidence, FDA clearance, Category I coding, payer policies, and provider training can combine to produce repeatable patient access.
The synthesis
The strongest evidence is the Q1 2026 acceleration: sales increased 79.5%, gross margin reached 86.4%, operating loss improved 24.2%, and operating cash use declined 23.3%. The constraint is equally clear: the company remains deeply loss-making, public-company overhead is heavy, customer concentration exists, internal controls require remediation, and financing has increased the share count. Students and investors should monitor hospital penetration, payer policies, full-reimbursement mix, quarterly cash burn, diluted shares, and progress in additional indications. If commercialization scales faster than overhead and dilution, the high-margin device model can create meaningful operating leverage. If access expands slowly, the company may continue funding clinical and commercial development through equity issuance.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.